Medtech 3.0 & Creating Unicorns
Scott will deliver a Keynote address on February 18th and share his vision for the future of medtech and why now is the time to build, not backpedal. He'll share insights and experiences from the past and provide his unique perspective on the opportunities ahead. His session will address thinking big during the COVID era and the digital transformation to improve access to care, lower cost and improve patient outcomes.
Huennekens has more than 25 years of experience in the medical device industry, specializing in clinical advancement through innovative R&D and technology-based initiatives. He currently serves as Executive Chairman of the Board for Acutus Medical (IPO in 2020). He has held a number of executive leadership roles within the healthcare industry, accelerating the next generation of digital surgery for Verb Surgical and leading Volcano Corporation, an image guided therapy device company, to its IPO in 2006. He holds an MBA from Harvard University and a BS in Business Administration from the University of Southern California. Huennekens currently sits on the boards of public companies Viewray and NuVasive.
Executive Chairman, Acutus Medical
Conversation With A Medtech Visionary
In this conversation, we'll tap into the experiences, wisdom and projections of medtech mogul, Paul LaViolette. We'll learn what Paul and his partners are up to with their new Medtech Convergence Fund and we'll have some fun talking about stories from the past and opportunities of the future.
Managing Partner, SV Health Investors, Medtech Convergence Fund
CEO, Life Science Intelligence
Medtech Venture Capital in 2021: What Investments Will We See?
In this panel we'll talk to active VCs about the types of deals they are in now and we'll find out what new deals they are looking for in 2021 and beyond.
The panel will be moderated by Lisa Carmel. Lisa is an industry insider, VP of Strategy with Ximedica, and she advises top medtech startups and accelerators, while also serving on the board of various organizations.
Partner, SV Health Investors
Amy Belt Raimundo
Managing Director, Kaiser Permanent Ventures
Partner, Gilde Healthcare Partners
General Partner, US Venture Partners
Venture Partner, Epidarex Capital
Venture Partner, Sante Ventures
Principal, New Enterprise Associates
Vice President Strategy, Ximedica
Intuitive Ventures, Intuitive Surgical
Medtech M&A Post COVID
In this panel we'll look at medtech M&A coming out of COVID. What kind of deals are strategics looking for? How has their strategy changed (or not changed) as a result of what we've learned? What deals will see in 2021 and beyond?
The panel will be moderated by industry insider and Alira Health Senior Partner & VP, David Uffer.
Additional panelists from major strategics to be announced soon.
VP of Global Corporate Development, Strategy and Strategic Relationships, Teleflex
Senior Partner & VP, Alira Health
How (& When) to Engage Corporates
This panel will be moderated by industry veteran and ex-J&J executive Nicholas Pachuda. Nick's panelists will include strategics and corporate investors with decades of experience working with entrepreneurs from seed to late stage. They'll share insights, success stories (plus a few war stories), and provide a strategic partnering roadmap for medical technology innovators and their investors.
Additional Panelists Announced Soon.
Sr. Director New Ventures, Johnson & Johnson Innovation
Global Head, Johnson & Johnson Innovation JLABS
Innovation & New Ventures, Pure Medtech Advisors
What's Coming Next?
Additional details and panelists announced soon.
General Partner, Head of Business & Corporate Development, Google Life Sciences, Verily Ventures
Healthcare and Tech Investor and Innovator, Google, Roche, Harvard, Dana-Farber Cancer Institute
More Investor, Strategic & Thought-Leader Panels Coming
Check back regularly as we are building content for our 2021 program now. We will deliver insightful and thought-provoking panel sessions with investors, strategics and innovators that are on the forefront of the medtech ecosystem.